Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.23 -2.5%	$4.09	$1.00 ▼ $5.87	$37.24M	0.8	143,896 shs	19,818 shs
ENGN enGene	$3.15 -4.3%	$3.71	$2.65 ▼ $11.00	$160.98M	-0.4	128,845 shs	79,121 shs
FDMT 4D Molecular Therapeutics	$4.13 +1.0%	$3.60	$2.24 ▼ $28.93	$191.32M	2.84	826,597 shs	595,805 shs
PBYI Puma Biotechnology	$3.19 -6.2%	$3.23	$2.23 ▼ $4.13	$158.57M	1.29	443,749 shs	314,744 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	0.00%	-3.86%	+1.44%	+12.20%	+126.20%
ENGN enGene	0.00%	-5.41%	-26.57%	-36.49%	-62.32%
FDMT 4D Molecular Therapeutics	0.00%	-5.92%	+14.72%	+5.36%	-81.87%
PBYI Puma Biotechnology	0.00%	-4.78%	-1.85%	-9.12%	+3.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	1.8376 of 5 stars	3.3	3.0	0.0	1.7	0.0
ENGN enGene	2.7318 of 5 stars	3.5	3.0	1.8	2.5	0.6
FDMT 4D Molecular Therapeutics	2.3742 of 5 stars	3.3	3.0	2.0	1.7	0.6
PBYI Puma Biotechnology	4.0619 of 5 stars	3.5	2.0	1.9	4.2	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	183.69% Upside
ENGN enGene	3.00	Buy	$23.29	639.23% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	615.63% Upside
PBYI Puma Biotechnology	3.00	Buy	$7.00	119.44% Upside

Current Analyst Ratings Breakdown

Latest ATHE, FDMT, ENGN, and PBYI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/29/2025	ENGN enGene	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$18.00 ➝ $18.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/22/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
ENGN enGene	N/A	N/A	N/A	N/A	$4.45 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	4,783.57	N/A	N/A	$11.05 per share	0.37
PBYI Puma Biotechnology	$232.71M	0.68	$0.85 per share	3.75	$1.88 per share	1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
ENGN enGene	-$55.14M	-$1.65	N/A	N/A	N/A	N/A	-32.60%	-28.26%	N/A
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/14/2025 (Estimated)
PBYI Puma Biotechnology	$30.28M	$0.77	4.14	8.39	N/A	16.37%	49.35%	18.25%	7/30/2025 (Estimated)

Latest ATHE, FDMT, ENGN, and PBYI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/10/2025	Q2 2025	ENGN enGene	-$0.4768	-$0.51	-$0.0332	-$0.51	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
ENGN enGene	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
ENGN enGene	0.09	12.66	12.66
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
PBYI Puma Biotechnology	0.11	1.53	1.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
ENGN enGene	64.16%
FDMT 4D Molecular Therapeutics	99.27%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
ENGN enGene	10.40%
FDMT 4D Molecular Therapeutics	9.60%
PBYI Puma Biotechnology	23.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
ENGN enGene	31	51.10 million	45.79 million	N/A
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
PBYI Puma Biotechnology	200	49.63 million	38.07 million	Optionable

ATHE, FDMT, ENGN, and PBYI Headlines

Recent News About These Companies